TY  - JOUR
A1  - Arnison, Paul G.
A1  - Bibb, Mervyn J.
A1  - Bierbaum, Gabriele
A1  - Bowers, Albert A.
A1  - Bugni, Tim S.
A1  - Bulaj, Grzegorz
A1  - Camarero, Julio A.
A1  - Campopiano, Dominic J.
A1  - Challis, Gregory L.
A1  - Clardy, Jon
A1  - Cotter, Paul D.
A1  - Craik, David J.
A1  - Dawson, Michael
A1  - Dittmann-Thünemann, Elke
A1  - Donadio, Stefano
A1  - Dorrestein, Pieter C.
A1  - Entian, Karl-Dieter
A1  - Fischbach, Michael A.
A1  - Garavelli, John S.
A1  - Goeransson, Ulf
A1  - Gruber, Christian W.
A1  - Haft, Daniel H.
A1  - Hemscheidt, Thomas K.
A1  - Hertweck, Christian
A1  - Hill, Colin
A1  - Horswill, Alexander R.
A1  - Jaspars, Marcel
A1  - Kelly, Wendy L.
A1  - Klinman, Judith P.
A1  - Kuipers, Oscar P.
A1  - Link, A. James
A1  - Liu, Wen
A1  - Marahiel, Mohamed A.
A1  - Mitchell, Douglas A.
A1  - Moll, Gert N.
A1  - Moore, Bradley S.
A1  - Mueller, Rolf
A1  - Nair, Satish K.
A1  - Nes, Ingolf F.
A1  - Norris, Gillian E.
A1  - Olivera, Baldomero M.
A1  - Onaka, Hiroyasu
A1  - Patchett, Mark L.
A1  - Piel, Jörn
A1  - Reaney, Martin J. T.
A1  - Rebuffat, Sylvie
A1  - Ross, R. Paul
A1  - Sahl, Hans-Georg
A1  - Schmidt, Eric W.
A1  - Selsted, Michael E.
A1  - Severinov, Konstantin
A1  - Shen, Ben
A1  - Sivonen, Kaarina
A1  - Smith, Leif
A1  - Stein, Torsten
A1  - Suessmuth, Roderich D.
A1  - Tagg, John R.
A1  - Tang, Gong-Li
A1  - Truman, Andrew W.
A1  - Vederas, John C.
A1  - Walsh, Christopher T.
A1  - Walton, Jonathan D.
A1  - Wenzel, Silke C.
A1  - Willey, Joanne M.
A1  - van der Donk, Wilfred A.
T1  - Ribosomally synthesized and post-translationally modified peptide natural products overview and recommendations for a universal nomenclature
JF  - Natural product reports : a journal of current developments in bio-organic chemistry
N2  - This review presents recommended nomenclature for the biosynthesis of ribosomally synthesized and post-translationally modified peptides (RiPPs), a rapidly growing class of natural products. The current knowledge regarding the biosynthesis of the >20 distinct compound classes is also reviewed, and commonalities are discussed.
Y1  - 2013
U6  - https://doi.org/10.1039/c2np20085f
SN  - 0265-0568
VL  - 30
IS  - 1
SP  - 108
EP  - 160
PB  - Royal Society of Chemistry
CY  - Cambridge
ER  - 
TY  - JOUR
A1  - Dschietzig, Thomas Bernd
A1  - Krause-Relle, Katharina
A1  - Hennequin, Maud
A1  - von Websky, Karoline
A1  - Rahnenfuhrer, Jan
A1  - Ruppert, Jana
A1  - Groena, Hans Juergen
A1  - Armbruster, Franz Paul
A1  - Bathgate, Ross A. D.
A1  - Aschenbach, Joerg R.
A1  - Forssmann, Wolf-Georg
A1  - Hocher, Berthold
T1  - Relaxin-2 does not Ameliorate Nephropathy in an experimental model of Type-1 Diabetes
JF  - Kidney & blood pressure research : official organ of the Gesellschaft für Nephrologie
N2  - Background/Aims: In diabetic nephropathy (DN), the current angiotensin-II-blocking pharmacotherapy is frequently failing. For diabetic cardiomyopathy (DC), there is no specific remedy available. Relaxin-2 (Rlx) - an anti-fibrotic, anti-inflammatory, and vasoprotecting peptide - is a candidate drug for both. Methods: Low-dose (32 mu g/kg/day) and high-dose (320 mu g/kg/day) Rlx were tested against vehicle (n = 20 each) and non-diabetic controls (n = 14) for 12 weeks in a model of type-1 diabetes induced in endothelial nitric oxide synthase knock-out (eNOS-KO) mice by intraperitoneal injection of streptozotocin. Results: Diabetic animals showed normal plasma creatinine, markedly increased albuminuria and urinary malonyldialdehyde, elevated relative kidney weight, glomerulosclerosis, and increased glomerular size, but no relevant interstitial fibrosis. Neither dose of Rlx affected these changes although the drug was active and targeted plasma levels were achieved. Of note, we found no activation of the renal TGF-beta pathway in this model. In the hearts of diabetic animals, no fibrotic alterations indicative of DC could be determined which precluded testing of the initial hypothesis. Conclusions: We investigated a model showing early DN without overt tubulo-interstitial fibrosis and activation of the TGF-beta-Smad-2/3 pathway. In this model, Rlx proved ineffective; however, the same may not apply to other models and types of diabetes.
KW  - Diabetic nephropathy
KW  - Diabetic cardiomyopathy
KW  - Fibrosis
KW  - Inflammation
KW  - Relaxin
Y1  - 2015
U6  - https://doi.org/10.1159/000368484
SN  - 1420-4096
SN  - 1423-0143
VL  - 40
IS  - 1
SP  - 77
EP  - 88
PB  - Karger
CY  - Basel
ER  -